Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.
Institute of Experimental Dermatology and Institute of Cardiogenetics, University of Lübeck, Lübeck, Germany.
Mov Disord. 2021 Jun;36(6):1381-1391. doi: 10.1002/mds.28506. Epub 2021 Feb 6.
The THAP1 gene encodes a transcription factor, and pathogenic variants cause a form of autosomal dominant, isolated dystonia (DYT-THAP1) with reduced penetrance. Factors underlying both reduced penetrance and the disease mechanism of DYT-THAP1 are largely unknown.
We performed transcriptome analysis on 29 cortical neuronal precursors derived from human-induced pluripotent stem cell lines generated from manifesting and nonmanifesting THAP1 mutation carriers and control individuals.
Whole transcriptome analysis showed a penetrance-linked signature with expressional changes more pronounced in the group of manifesting (MMCs) than in nonmanifesting mutation carriers (NMCs) when compared to controls. A direct comparison of the transcriptomes in MMCs versus NMCs showed significant upregulation of the DRD4 gene in MMCs. A gene set enrichment analysis demonstrated alterations in various neurotransmitter release cycle pathways, extracellular matrix organization, and deoxyribonucleic acid methylation between MMCs and NMCs. When specifically considering transcription factors, the expression of YY1 and SIX2 differed in MMCs versus NMCs. Further, THAP1 was upregulated in the group of MMCs.
To our knowledge, this is the first report systematically analyzing reduced penetrance in DYT-THAP1 in a human model using transcriptomes. Our findings indicate that transcriptional alterations during cortical development influence DYT-THAP1 pathogenesis and penetrance. We reinforce previously linked pathways including dopamine and eukaryotic translation initiation factor 2 alpha signaling in the pathogenesis of dystonia including DYT-THAP1 and suggest extracellular matrix organization and deoxyribonucleic acid methylation as mediators of disease protection. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
THAP1 基因编码一种转录因子,其致病性变体导致一种常染色体显性、孤立性肌张力障碍(DYT-THAP1),其外显率降低。导致外显率降低和 DYT-THAP1 疾病机制的因素在很大程度上尚不清楚。
我们对 29 个源自有症状和无症状 THAP1 突变携带者和对照个体的人诱导多能干细胞系衍生的皮质神经元前体细胞进行了转录组分析。
全转录组分析显示,与对照组相比,具有外显率相关特征的表达谱在表现型(MMCs)突变携带者组中比在非表现型突变携带者(NMCs)中更为明显。MMCs 与 NMCs 之间的转录组直接比较显示,DRD4 基因在 MMCs 中显著上调。基因集富集分析表明,在 MMCs 和 NMCs 之间,各种神经递质释放循环途径、细胞外基质组织和脱氧核糖核酸甲基化发生改变。当专门考虑转录因子时,YY1 和 SIX2 在 MMCs 与 NMCs 中的表达不同。此外,THAP1 在 MMCs 组中上调。
据我们所知,这是首次使用转录组在人类模型中系统分析 DYT-THAP1 中的外显率降低。我们的研究结果表明,皮质发育过程中的转录改变影响 DYT-THAP1 的发病机制和外显率。我们强化了先前与多巴胺和真核翻译起始因子 2α信号转导相关的途径在包括 DYT-THAP1 在内的肌张力障碍发病机制中的作用,并提出细胞外基质组织和脱氧核糖核酸甲基化作为疾病保护的介质。© 2021 作者。运动障碍由 Wiley 期刊公司代表国际帕金森和运动障碍协会出版。